Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer

[1]  K. Katsui,et al.  Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. , 2002, Anticancer research.

[2]  L. Milas,et al.  Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. , 2001, International journal of oncology.

[3]  J. Bellon,et al.  Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. , 2000, International journal of radiation oncology, biology, physics.

[4]  H. Choy.  Combining taxanes with radiation for solid tumors , 2000, International journal of cancer.

[5]  V. Georgoulias,et al.  Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer , 2000, Medical oncology.

[6]  H. Choy,et al.  A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. , 2000, Clinical lung cancer.

[7]  M. Hasegawa,et al.  Experimental study of the effects on apoptosis of docetaxel alone and in combination with irradiation. , 2000, Oncology Report.

[8]  L. Milas,et al.  Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  V. Georgoulias,et al.  Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma , 1999, British Journal of Cancer.

[10]  W. Symmans,et al.  Concurrent paclitaxel and radiation therapy for breast cancer. , 1999, Seminars in radiation oncology.

[11]  L. Milas,et al.  Combination of taxanes with radiation: preclinical studies. , 1999, Seminars in radiation oncology.

[12]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Vokes,et al.  Phase I study of docetaxel with concomitant thoracic radiation therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Milas,et al.  Docetaxel enhances tumor radioresponse in vivo. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  C. Hennequin,et al.  Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. , 1996, Cancer research.

[16]  P. Fumoleau,et al.  A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  V. Valero,et al.  Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Rubin,et al.  EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  P. Rubin,et al.  RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. , 1995, International journal of radiation oncology, biology, physics.

[20]  M. van Glabbeke,et al.  Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  田口鐵男.  Phase I clinical trial of RP56976 (docataxel) a new anticancer drug , 1994 .